Get the Stockscreener App
3.74
3.86%
-0.15
After Hours:
3.77
0.03
+0.80%
Recursion Pharmaceuticals Inc stock is traded at $3.74, with a volume of 10.38M.
It is down -3.86% in the last 24 hours and up +5.06% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
See More
Previous Close:
$3.89
Open:
$3.89
24h Volume:
10.38M
Relative Volume:
0.53
Market Cap:
$2.01B
Revenue:
$66.41M
Net Income/Loss:
$-559.78M
P/E Ratio:
-3.111
EPS:
-1.2022
Net Cash Flow:
$-328.09M
1W Performance:
-2.35%
1M Performance:
+5.06%
6M Performance:
+17.98%
1Y Performance:
-19.22%
1-Day Range:
$3.70
$3.90
1-Week Range:
$3.61
$4.16
52-Week Range:
$2.77
$7.18
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.74 | 2.01B | 66.41M | -559.78M | -328.09M | -1.2022 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
RXRX Stock Rises As Tempus AI Deal Resets Growth Story - StocksToTrade
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Short Interest & Short Float | Updated Sep 2026 $RXRX - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX) stock price, news, quote and history - Yahoo Finance UK
Recursion Pharmaceuticals (RXRX) Shares Just Moved, So What Is Driving Attention Now? - simplywall.st
Recursion Pharmaceuticals (RXRX) Stock Moves 2.02%: What You Should Know - Yahoo Finance
RXRX Extends Tempus Deal As Stock Climbs On Predictable Cash - timothysykes.com
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: High Potential Upside in the Biotech Sector - DirectorsTalk Interviews
RXRX Stock Grinds Higher As Insider Filings Stack Up - timothysykes.com
A data partnership shifts from potential $84 million in two-year fees to $42 million in committed payments over three - Stock Titan
Recursion Pharmaceuticals (NASDAQ: RXRX) Lowers Tempus Annual Fees to $14 Million - Kalkine Media
Recursion Pharmaceuticals, Inc. Grants Tempus Ai, Inc. Non-Exclusive License for Rna Foundation Model - marketscreener.com
Recursion, Tempus Expand AI and RNA Collaboration Agreements - TipRanks
Recursion Resets Tempus Data Pact and Licenses TxFM RNA Model in $12M Deal - TradingView
Recursion Pharmaceuticals Enters Amendment To Master Agreement With Tempus On Sept 15, 2026SEC Filing - TradingView
Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference - Yahoo Finance
Is Recursion Pharmaceuticals (RXRX) A Bargain As Its Shares Rebound? - Yahoo Finance
Recursion Pharmaceuticals Inc (RXRX) Stock Price, Quote, News & History - Benzinga
RXRX Stock Holds Support As Insider Form 4s Hit Tape - StocksToTrade
RXRX Stock Steadies As Insider Activity Draws Trader Focus - timothysykes.com
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX) Options ChainYahoo Finance - Yahoo! Finance Canada
RXRX Stock Holds Steady As Insider Form 4 Filings Stack Up - timothysykes.com
Recursion Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Recursion Pharmaceuticals (RXRX): Can Its AI Platform Translate Into Clinical Wins? - RTTNews
Recursion Pharmaceuticals (RXRX) CFO’s 5,396-share move wasn’t a sale - Stock Titan
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know - finance.yahoo.com
Recursion Pharmaceuticals Stock (RXRX) Opinions on Recent Conference Updates and Partnerships - Moomoo
Recursion Pharma CEO Najat Khan sells $78,822 in stock By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals (RXRX) CEO and President Najat Khan Sells 22,408 Shares - GuruFocus
Recursion Pharma CEO Najat Khan sells $78,822 in stock - investing.com
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Khan Najat - Moomoo
Recursion Pharmaceuticals CEO Najat Khan Sells 22,408 Shares Under 10b5-1 Plan - Kalkine Media
Recursion Pharmaceuticals (NASDAQ:RXRX) Trades Active As Small-Caps Wobble - Kalkine Media
Recursion (NASDAQ: RXRX) CEO sells 22K shares under preset plan - Stock Titan
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today - Yahoo Finance
Recursion Pharmaceuticals Tokenized Stock (Ondo) price today, RXRXon to USD live price, marketcap and chart - CoinMarketCap
Recursion Pharmaceuticals Stock Short Interest Falls to 34.79% - Moomoo
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
2 Beaten-Down Stocks to Avoid Right Now - theglobeandmail.com
AI in Pharmaceutical Market to Hit USD 48.43 Billion by 2035, Growing at 31.76% CAGR – SNS Insider - GlobeNewswire Inc.
Penny Stocks To ResearchSeptember 6th - MarketBeat
Penny Stocks To Follow NowSeptember 5th - MarketBeat
RXRX Tightens Spending As AI Drug Platform Gains Traction - timothysykes.com
RXRX Tightens Cash Burn As AI Drug Pipeline Advances - StocksToTrade
RXRX Tightens Costs As AI Drug Pipeline Advances - timothysykes.com
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report? - Yahoo Finance
$Recursion Pharmaceuticals (RXRX.US)$ - Moomoo
RXRX Stock Steadies As AI Drug Engine Tightens Spending - StocksToTrade
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? - The Globe and Mail
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):